Enanta Pharmaceuticals Inc (ENTA)

[stockbettor]

Probably will not find out anything new, but should be nice publicity as the approval date begins to approach:

ACG: From HCV to the Microbiome
Published: Oct 16, 2014

By Nancy Walsh, Senior Staff Writer, MedPage Today

The annual meeting of the American College of Gastroenterology (ACG) kicks off tomorrow in Philadelphia, when more than 4,000 gastroenterologists gather for clinical reviews and postgraduate courses over the weekend and then for the scientific sessions beginning on Monday morning.

This will be "the premier GI clinical event of the year," said ACG president Harry E. Sarles, Jr., MD.

The top 10 abstracts are being featured in the Presidential Plenary session on Monday morning, said John R. Saltzman, MD, director of endoscopy at Brigham and Women's Hospital in Boston, who chaired the education affairs committee.

Among the most notable is a study of an oral ribavirin-free regimen for hepatitis C virus (HCV) genotype 1b. This regimen, which includes ABT-450 along with ombitasvir and dasabuvir, found a sustained viral response of 99%, which was "incredible," according to Saltzman.

That will be followed by a presentation on the treatment of HCV genotype 1b-infected patients who have cirrhosis using a regimen of ABT-450, ombitasvir, dasabuvir, plus ribavirin. In this study, some liver-related parameters such as platelet counts improved, he pointed out.

"The hepatitis part of the meeting is extremely strong this year," Saltzman said.

http://www.medpagetoday.com/MeetingCoverage/ACG/48107